KWM
INDP icon

Kingsview Wealth Management’s Indaptus Therapeutics INDP Stock Holding History

Kingsview Wealth Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8
Closed -$5K – 753
2020
Q3 		$5K Hold
8
– – ﹤0.01% 609
2020
Q2 		$5K Buy
8
+3
+60% +$1.85K ﹤0.01% 576
2020
Q1 		$2K Hold
5
– – ﹤0.01% 483
2019
Q4 		$5K Hold
5
– – ﹤0.01% 469
2019
Q3 		$8K Hold
5
– – ﹤0.01% 419
2019
Q2 		$47K Buy
+5
New +$63.1K 0.01% 406

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kingsview Wealth Management's INDP Position: Q4 2020 in Review

Kingsview Wealth Management sold out of Indaptus Therapeutics (INDP) in Q4 2020, closing a stake of 8 shares — an estimated $5K sold.

Kingsview Wealth Management first reported a position in INDP in Q2 2019 and held it in 6 quarters. The position peaked at $47K in Q2 2019. 18 funds tracked by Wall St. Rank hold INDP as of Q4 2020.

  • Kingsview Wealth Management reported no remaining Indaptus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Kingsview Wealth Management sold 8 Indaptus Therapeutics shares in Q4 2020, an estimated $5K.
  • Kingsview Wealth Management first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 6 quarters.
  • Kingsview Wealth Management's Indaptus Therapeutics position peaked at $47K in Q2 2019.
  • 18 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2020.

Based on Kingsview Wealth Management's 13F filing for Q4 2020, filed 16 Feb 2021.